The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1372
Gabapentin Enacarbil (Horizant) for Restless Legs Syndrome
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Gabapentin enacarbil (Horizant – GlaxoSmithKline), a new extended-release (ER) tablet formulation of gabapentin, has been approved by the FDA for treatment of moderate-to-severe restless legs syndrome (RLS). The immediate-release (IR) formulation of gabapentin (Neurontin,and others), which is approved for treatment of epilepsy and postherpetic neuralgia, has been used for many years to treat RLS.1 Another ER tablet formulation of gabapentin (Gralise) has been approved by the FDA for treatment of postherpetic neuralgia.

STANDARD TREATMENT — The nonergot-derived dopamine agonists pramipexole and ropinirole were previously the only drugs approved in the US for treatment of RLS.2,3 Both can cause nausea, orthostatic hypotension and sedation; sudden episodes of sleep without warning and impulsive behaviors, such as ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Gabapentin Enacarbil (Horizant) for Restless Legs Syndrome
Article code: 1372b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian